Advances in Therapy

, Volume 27, Issue 7, pp 444–457 | Cite as

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

  • Yuji Yasuda
  • Ryoya Komatsu
  • Kenji Matsushita
  • Taketsugu Minami
  • Yutaka Suehiro
  • Hiroshi Sawata
  • Noriko Nakura
  • Ralf K. Jaeger
  • Maria Lattanzi
Open Access
Original Research



The substantial pandemic (A/H1N1v) influenza disease burden in children highlights the need for effective vaccination. We report the results of modern cell culture technology, lower doses of antigen, and different doses of MF59® adjuvant (Novartis Vaccines, Marburg, Germany), on the immunogenicity and safety profile in a healthy Japanese pediatric population.


A total of 123 children from 6 months to 19 years of age were randomly assigned in a 1:1 ratio to receive, at 21-day intervals, two doses of either 3.75 μg antigen with 50% of the standard MF59 dose (group A) or 7.5 μg antigen and 100% standard MF59 dose (group B). Antibody levels were measured by hemagglutinin inhibition (HI) and microneutralization assays on day 1 and on days 22 and 43 (3 weeks after the first and second vaccinations, respectively). Solicited adverse events were reported for 7 days after each injection and spontaneous events were reported throughout the study period.


At 3 weeks after the first vaccination, seroprotective HI antibodies (titers ≥40) were observed in 56% and 78% of subjects from groups A and B, respectively; 100% in both groups exhibited HI titers ≥40 after the second dose. The reactogenicity profile was acceptable, with local and systemic reactions described as mainly mild to moderate in severity. Five serious adverse events were reported, but none related to the study vaccine.


One dose of cell culture-derived A/H1N1v vaccine containing 7.5 μ g antigen with the full MF59 adjuvant dose was immunogenic and well tolerated in healthy Japanese children, meeting all three European Union Committee for Medicinal Products for Human Use (EU CHMP) licensure criteria. Two doses of 3.75 μg antigen with 50% of the standard MF59 dose fulfilled these licensure criteria.


cell culture vaccine children A/H1N1v influenza MF59 adjuvant 


  1. 1.
    World Health Organization. DG statement following the meeting of the Emergency Committee. Available at: Accessed June 11, 2009.
  2. 2.
    Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children—Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:400–402.Google Scholar
  3. 3.
    World Health Organization. Pandemic H1N1 2009-Update 86 Geneva. Available at: Accessed January 29, 2010.
  4. 4.
    Kamigaki T, Oshitani H. Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan. PLoS Curr Influenza. 2009:RRN1139.Google Scholar
  5. 5.
    Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58:521–524.Google Scholar
  6. 6.
    Jordan R, Connock M, Albon E, et al. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine. 2006;24:1047–1062.CrossRefPubMedGoogle Scholar
  7. 7.
    Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001;344:889–896.CrossRefPubMedGoogle Scholar
  8. 8.
    Medlock J, Galvani AP. Optimizing influenza vaccine distribution. Science. 2009;325:1705–1708.CrossRefPubMedGoogle Scholar
  9. 9.
    US Food and Drug Administration, Center for Biological Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Available at: Accessed June 1, 2010.
  10. 10.
    Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009;361:2424–2435.CrossRefPubMedGoogle Scholar
  11. 11.
    Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405–2413.CrossRefPubMedGoogle Scholar
  12. 12.
    Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, doubleblind, randomised, placebo-controlled trial. Lancet. 2010;375:56–66.CrossRefPubMedGoogle Scholar
  13. 13.
    Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2010;375:41–48.CrossRefPubMedGoogle Scholar
  14. 14.
    Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet. 2010;375:49–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009;361:2414–2423.CrossRefPubMedGoogle Scholar
  16. 16.
    Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA. 2010;303:37–46.CrossRefPubMedGoogle Scholar
  17. 17.
    Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med. 2010;362:370–372.CrossRefPubMedGoogle Scholar
  18. 18.
    Banzhoff A, Gasparini R, Laghi-Pasini F, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4:e4384.CrossRefPubMedGoogle Scholar
  19. 19.
    Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008;197:667–675.CrossRefPubMedGoogle Scholar
  20. 20.
    Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370:580–589.CrossRefPubMedGoogle Scholar
  21. 21.
    Stephenson I, Nicholson KG, Hoschler K, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med. 2008;359:1631–1633.CrossRefPubMedGoogle Scholar
  22. 22.
    Worlth Health Organization. Global alert and response: WHO recommendations on pandemic (H1N1) 2009 vaccines. Available at: Accessed June 1, 2009.
  23. 23.
    Centers for Disease Control and Prevention. Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives - 12 states, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1341–1344.Google Scholar
  24. 24.
    O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007;6:699–710.CrossRefPubMedGoogle Scholar
  25. 25.
    Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine. 2008;26:3209–3222.CrossRefPubMedGoogle Scholar
  26. 26.
    Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis. 2009;200:841–848.CrossRefPubMedGoogle Scholar
  27. 27.
    Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37:937–943.PubMedGoogle Scholar
  28. 28.
    Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28:563–571.CrossRefPubMedGoogle Scholar
  29. 29.
    CHMP. Guideline on Influenza Vaccines Pepared from Viruses with the Potential to Cause a Pandemic and Intended for Use Outside of the Core Dossier Context EMEA/CPMP/VWP/263499/2006, 24 January 2007. Available at: Accessed June 1, 2010.
  30. 30.
    CHMP. Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application (Revision, EMEA/CPMP/VEG/4717/2002-Rev1). 18 December 2008. Available at: Accessed June 1, 2010.
  31. 31.
    Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr., Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225–231.CrossRefPubMedGoogle Scholar
  32. 32.
    Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355:31–40.CrossRefPubMedGoogle Scholar
  33. 33.
    Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine. 2009;27:6291–6295.CrossRefPubMedGoogle Scholar
  34. 34.
    Center for Disease Control and Prevention. Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep. 2009;58:1100–1101.Google Scholar
  35. 35.
    Wise J. Children are likely to need two doses of swine flu vaccine. BMJ. 2009;339:b3969.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Yuji Yasuda
    • 1
  • Ryoya Komatsu
    • 2
  • Kenji Matsushita
    • 3
  • Taketsugu Minami
    • 4
  • Yutaka Suehiro
    • 5
  • Hiroshi Sawata
    • 6
  • Noriko Nakura
    • 6
  • Ralf K. Jaeger
    • 7
  • Maria Lattanzi
    • 8
  1. 1.Yasuda ClinicMinami-ku, KyotoJapan
  2. 2.Ryoya Komatsu ClinicIzumisano, OsakaJapan
  3. 3.Kamoike Seikyou ClinicKamoike, KagoshimaJapan
  4. 4.Minami ClinicKamoike, KagoshimaJapan
  5. 5.Saiseikai Nakatsu HospitalKita-ku, OsakaJapan
  6. 6.Novartis PharmaMinato-ku, TokyoJapan
  7. 7.Novartis Vaccines and DiagnosticsMarburgGermany
  8. 8.Clinical DevelopmentNovartis Vaccines and DiagnosticsSienaItaly

Personalised recommendations